Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: SPARK Healthy Sleep [NA]
Indiana University reports that the SPARK Healthy Sleep trial is currently recruiting participants to study sleep disturbances in schizophre…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI [NA]
This clinical trial assesses MI-CBTech, a mobile intervention aimed at improving community integration for homeless-experienced veterans wit…
-
FDA approval · 2025-11-05FDA Approved: CAPLYTA — Supplemental Application (Intra-Cellular Therapies, Inc)
FDA approves a supplemental application for CAPLYTA (lumateperone) from Intra-Cellular Therapies, Inc.
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) [Phase 3]
Phase 3 CONNEX-1 trial evaluated Iclepertin's impact on cognition and functional capacity in schizophrenia. The study is completed and resul…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Effectiveness of Motivation Skills Training (MST) [NA]
A Columbia University-led clinical trial is evaluating the effectiveness of Motivation Skills Training (MST) for schizophrenia and schizoaff…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Optimizing CBSST With Executive Function Training for Schizophrenia [NA]
This trial update notes ongoing research optimizing CBSST with executive function training for schizophrenia and schizoaffective disorder, w…
-
FDA approval · 2025-11-04FDA Approved: RISPERIDONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for RISPERIDONE from Amneal Pharmaceuticals LLC under an ANDA, authorizing a new or updated generic …
-
FDA label_change · 2025-10-30FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Patriot Pharmaceuticals LLC)
FDA approved a supplemental application for haloperidol decanoate submitted by Patriot Pharmaceuticals LLC, resulting in a label update for …
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia [Phase 2]
AbbVie completed a Phase 2 trial evaluating 15 mg and 30 mg doses of emraclidine (CVL-231) in schizophrenia, with the results posted.
-
EMA approval · 2025-10-28EMA Authorised: Abilify Maintena (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.
The European Medicines Agency authorised Abilify Maintena (aripiprazole) with Otsuka Pharmaceutical Netherlands B.V. as the marketing author…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder [Phase 3]
Open-label, flexible-dose study to evaluate the long-term safety and tolerability of cariprazine in pediatric participants with schizophreni…
-
FDA approval · 2025-10-23FDA Approved: OLANZAPINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for olanzapine from Dr. Reddy's Laboratories Limited.
-
FDA label_change · 2025-10-23FDA Approved: OLANZAPINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for olanzapine from Aurobindo Pharma Limited. This action typically involves labeling changes for th…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia [Phase 2]
A Phase 2 randomized, double-blind, placebo-controlled trial evaluating LB-102 for acute schizophrenia has completed, with results posted.
-
FDA approval · 2025-10-22FDA Approved: ARIPIPRAZOLE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved the original application for aripiprazole from Quagen Pharmaceuticals LLC, marking the availability of a generic aripiprazole p…
-
CLINICAL_TRIALS safety_alert · 2025-10-21Clinical Trial Update: Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
An observational safety study evaluating ADASUVE (loxapine inhalation powder) for agitation associated with schizophrenia or Bipolar I disor…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia [Phase 3]
Phase 3 trial evaluating adverse events and changes in disease activity with oral cariprazine in adults with schizophrenia has been terminat…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 clinical trial completion update for two digital therapeutics targeting experiential negative symptoms in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 extension study update for a digital therapeutic by Click Therapeutics addressing experiential negative symptoms in schizophrenia; t…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia [Phase 2]
Phase 2 translational and neurocomputational evaluation of a dopamine D1 receptor partial agonist for schizophrenia has completed, with resu…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia [NA]
This clinical trial update outlines a prospective cohort study evaluating the clinical effectiveness of the investigational digital therapeu…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Mobile Self-Tracking of Mental Health [NA]
This clinical trial update notes the completion and posting of results for a mobile self-tracking study addressing mental health conditions …
-
EMA approval · 2025-10-14EMA Authorised: Okedi (risperidone) — Laboratorios Farmacéuticos Rovi, S.A.
The European Medicines Agency authorised Okedi, a risperidone product, for the treatment of schizophrenia.
-
EMA approval · 2025-10-09EMA Authorised: Adasuve (loxapine) — Ferrer Internacional S.A.
The EMA authorised Adasuve (loxapine) by Ferrer Internacional S.A. for use in schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Neurophysiologic Biomarkers for Cognitive Rehabilitation
A clinical study sponsored by the VA Office of Research and Development is investigating neurophysiologic biomarkers to guide cognitive reha…